Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Preferred Stock Liabilities (2023 - 2024)

Camp4 Therapeutics (CAMP) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $162.1 million as the latest value for Q3 2024.

  • Quarterly Preferred Stock Liabilities changed 0.0% to $162.1 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $162.1 million through Sep 2024, changed 0.0% year-over-year, with the annual reading at $162.1 million for FY2023, N/A changed from the prior year.
  • Preferred Stock Liabilities hit $162.1 million in Q3 2024 for Camp4 Therapeutics, roughly flat from $162.1 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $162.1 million in Q3 2023 to a low of $162.1 million in Q3 2023.